Immuno-Oncology Deal Trends, 2011-15

Description: Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated. The Big Pharma and Mid Pharma peer sets are an integral part of development and have been furthering efforts via deal-making. The peer groups’ deal volume in immuno-oncology has grown over sevenfold from 2011 to 2015.

More than 50% of the immuno-oncology deals between 2011 and 2015 involved testing combinations that may eventually address previously unresponsive patients and/or additional tumor types. Combination agreements are structured differently to traditional licensing deals and are often pre-competitive in nature, early stage, and involve only one or two single studies.

This report addresses the following questions:
- What is the growth of immuno-oncology deal-making over the last five years in volume and dollar value, and how does that compare with overall oncology deal-making?
- Who are the top players in immuno-oncology deal-making, and what were the structures of their key deals?
- Which solid and hematological tumor indications and anticancer immunotherapy targets are most involved immuno-oncology deals?
- What strategies are being implemented by some of the most influential companies in immuno-oncology?

Contents:

Executive Summary

Immuno-Oncology: A Brief Introduction

1. Immuno-oncology has sparked multiple industry, academic, and government initiatives
2. Bibliography

Key Trends in Immuno-Oncology Deal-Making

3. Immuno-oncology deal volume has rapidly increased
4. Bristol-Myers Squibb and Merck & Co were the top immuno-oncology dealmakers
5. Immuno-oncology represented most of the overall oncology deal value
6. Solid tumors, especially lung cancer and melanoma, led immuno-oncology deals
7. Non-Hodgkin's lymphoma and myeloma decreasing in overall share of deals
8. PD-L1/PD-1 dominated immuno-oncology deals
9. Immuno-oncology targets vary across indications
10. Bibliography

Immuno-Oncology Combinations: Collaborative Efforts

11. Combinations are the driving force in immuno-oncology deal-making
12. Combination collaborations have unique characteristics
13. Combination collaborations
14. Bibliography

Immuno-Oncology Deal-Making Case Studies

15. AstraZeneca has high hopes for durvalumab in combinations and in hematological cancers
16. Bristol-Myers Squibb aims to extend immuno-oncology leadership
17. Celgene is trying to make an impact in hematological cancers
18. GlaxoSmithKline looks to alternative immuno-oncology targets
19. Merck & Co is banking on Keytruda combinations
20. Roche's atezolizumab advances in bladder cancer, but combinations and non-PD-L1 targets are of importance
21. Bibliography
Appendix

22. Scope
23. Methodology

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3783263/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Immuno-Oncology Deal Trends, 2011-15
Web Address: http://www.researchandmarkets.com/reports/3783263/
Office Code: SCBRK4N7

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>USD 5000</th>
<th>USD 17500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single User</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr   [ ] Mrs   [ ] Dr   [ ] Miss   [ ] Ms   [ ] Prof
First Name: ___________________________________________ Last Name: _______________________________________
Email Address: * _______________________________________
Job Title: ____________________________________________
Organisation: ________________________________________
Address: ____________________________________________
City: _______________________________________________
Postal / Zip Code: ___________________________________
Country: ___________________________________________
Phone Number: ______________________________________
Fax Number: ________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World